Literature DB >> 18752004

Vascular targeted therapies in oncology.

Dietmar W Siemann1, Michael R Horsman.   

Abstract

Neovascularization is intimately involved in tumor survival, progression, and spread, factors known to contribute significantly to treatment failures. Thus, strategies targeting the tumor blood vessel support network may offer not only unique therapeutic opportunities in their own right, but also novel means of enhancing the efficacies of conventional anticancer treatments. This article reviews one such therapeutic approach directed at the tumor blood vessel support network. Vascular disrupting therapies seek the destruction of the established neovasculature of actively growing tumors. The goal of these therapies is to cause a rapid and catastrophic shutdown in the vascular function of the tumor in order to arrest the blood flow and produce tumor cell death as a result of oxygen and nutrient deprivation and the build up of waste products.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18752004      PMCID: PMC2788502          DOI: 10.1007/s00441-008-0646-0

Source DB:  PubMed          Journal:  Cell Tissue Res        ISSN: 0302-766X            Impact factor:   5.249


  42 in total

1.  Effect of the second-generation vascular disrupting agent OXi4503 on tumor vascularity.

Authors:  Howard W Salmon; Dietmar W Siemann
Journal:  Clin Cancer Res       Date:  2006-07-01       Impact factor: 12.531

2.  Enhancement of radiation therapy by the novel vascular targeting agent ZD6126.

Authors:  Dietmar W Siemann; Amyn M Rojiani
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-05-01       Impact factor: 7.038

3.  Population kinetics of carcinoma cells, capillary endothelial cells, and fibroblasts in a transplanted mouse mammary tumor.

Authors:  I F Tannock
Journal:  Cancer Res       Date:  1970-10       Impact factor: 12.701

Review 4.  Current development status of small-molecule vascular disrupting agents.

Authors:  David J Chaplin; Michael R Horsman; Dietmar W Siemann
Journal:  Curr Opin Investig Drugs       Date:  2006-06

Review 5.  Differentiation and definition of vascular-targeted therapies.

Authors:  Dietmar W Siemann; Michael C Bibby; Graham G Dark; Adam P Dicker; Ferry A L M Eskens; Michael R Horsman; Dieter Marmé; Patricia M Lorusso
Journal:  Clin Cancer Res       Date:  2005-01-15       Impact factor: 12.531

Review 6.  Vascular-targeting therapies for treatment of malignant disease.

Authors:  Dietmar W Siemann; David J Chaplin; Michael R Horsman
Journal:  Cancer       Date:  2004-06-15       Impact factor: 6.860

7.  Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid.

Authors:  W R Wilson; A E Li; D S Cowan; B G Siim
Journal:  Int J Radiat Oncol Biol Phys       Date:  1998-11-01       Impact factor: 7.038

8.  ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature.

Authors:  Peter D Davis; Graeme J Dougherty; David C Blakey; Susan M Galbraith; Gillian M Tozer; Angela L Holder; Matthew A Naylor; John Nolan; Michael R L Stratford; David J Chaplin; Sally A Hill
Journal:  Cancer Res       Date:  2002-12-15       Impact factor: 12.701

9.  Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models.

Authors:  David C Blakey; F Russell Westwood; Mike Walker; Gareth D Hughes; Peter D Davis; Sue E Ashton; Anderson J Ryan
Journal:  Clin Cancer Res       Date:  2002-06       Impact factor: 12.531

10.  In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug.

Authors:  K Grosios; S E Holwell; A T McGown; G R Pettit; M C Bibby
Journal:  Br J Cancer       Date:  1999-12       Impact factor: 7.640

View more
  32 in total

1.  A pharmacokinetic and safety study of single dose intravenous combretastatin A4 phosphate in Chinese patients with refractory solid tumours.

Authors:  Xuexin He; Su Li; He Huang; Zhiming Li; Likun Chen; Sheng Ye; Jiajia Huang; Jing Zhan; Tongyu Lin
Journal:  Br J Clin Pharmacol       Date:  2011-06       Impact factor: 4.335

2.  Low Z target switching to increase tumor endothelial cell dose enhancement during gold nanoparticle-aided radiation therapy.

Authors:  Ross I Berbeco; Alexandre Detappe; Panogiotis Tsiamas; David Parsons; Mammo Yewondwossen; James Robar
Journal:  Med Phys       Date:  2016-01       Impact factor: 4.071

3.  Multiparametric MRI biomarkers for measuring vascular disrupting effect on cancer.

Authors:  Huaijun Wang; Guy Marchal; Yicheng Ni
Journal:  World J Radiol       Date:  2011-01-28

4.  Support of a free radical mechanism for enhanced antitumor efficacy of the microtubule disruptor OXi4503.

Authors:  Lori Rice; Christine Pampo; Sharon Lepler; Amyn M Rojiani; Dietmar W Siemann
Journal:  Microvasc Res       Date:  2010-10-23       Impact factor: 3.514

5.  Leukemia regression by vascular disruption and antiangiogenic therapy.

Authors:  Gerard J Madlambayan; Amy M Meacham; Koji Hosaka; Saad Mir; Marda Jorgensen; Edward W Scott; Dietmar W Siemann; Christopher R Cogle
Journal:  Blood       Date:  2010-05-14       Impact factor: 22.113

6.  High glucose concentration produces a short-term increase in pERK1/2 and p85 proteins, having a direct angiogenetic effect by an action similar to VEGF.

Authors:  Candida Zuchegna; Ferdinando Carlo Sasso; Mario Felice Tecce; Anna Capasso; Luigi Elio Adinolfi; Antonella Romano; Silvia Bartollino; Antonio Porcellini; Ciro Costagliola
Journal:  Acta Diabetol       Date:  2020-03-04       Impact factor: 4.280

Review 7.  The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents.

Authors:  Dietmar W Siemann
Journal:  Cancer Treat Rev       Date:  2010-06-08       Impact factor: 12.111

8.  Diverse responses to vascular disrupting agent combretastatin a4 phosphate: a comparative study in rats with hepatic and subcutaneous tumor allografts using MRI biomarkers, microangiography, and histopathology.

Authors:  Junjie Li; Feng Chen; Yuanbo Feng; Marlein Miranda Cona; Jie Yu; Alfons Verbruggen; Jian Zhang; Raymond Oyen; Yicheng Ni
Journal:  Transl Oncol       Date:  2013-02-01       Impact factor: 4.243

9.  Hepatocellular Carcinoma: Intra-arterial Delivery of Doxorubicin-loaded Hollow Gold Nanospheres for Photothermal Ablation-Chemoembolization Therapy in Rats.

Authors:  Junjie Li; Min Zhou; Fengyong Liu; Chiyi Xiong; Wanqin Wang; Qizhen Cao; Xiaoxia Wen; J David Robertson; Xin Ji; Y Andrew Wang; Sanjay Gupta; Chun Li
Journal:  Radiology       Date:  2016-06-27       Impact factor: 11.105

10.  The vascular disrupting activity of OXi8006 in endothelial cells and its phosphate prodrug OXi8007 in breast tumor xenografts.

Authors:  Tracy E Strecker; Samuel O Odutola; Ramona Lopez; Morgan S Cooper; Justin K Tidmore; Amanda K Charlton-Sevcik; Li Li; Matthew T MacDonough; Mallinath B Hadimani; Anjan Ghatak; Li Liu; David J Chaplin; Ralph P Mason; Kevin G Pinney; Mary Lynn Trawick
Journal:  Cancer Lett       Date:  2015-09-01       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.